NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report.
Barreiro-de Acosta
M
M
Gastroenterology, University Hospital of Santiago de Compostela, Spain. manubarreiro@hotmail.com
Ouburg
S
S
Morré
S A
SA
Crusius
J B A
JB
Lorenzo
A
A
Potel
J
J
Salvador-Peña
A
A
Domínguez-Muñoz
J E
JE
D000068879:Adalimumab; D000328:Adult; D017668:Age of Onset; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy* / Q000235:genetics*; D016207:Cytokines / Q000378:metabolism; D005260:Female; D005819:Genetic Markers; D005838:Genotype; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D053473:Nod2 Signaling Adaptor Protein / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D020133:Reverse Transcriptase Polymerase Chain Reaction; D051197:Toll-Like Receptor 4 / Q000235:genetics*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D005819:Genetic Markers; D018950:Lipopolysaccharide Receptors; C429018:NOD2 protein, human; D053473:Nod2 Signaling Adaptor Protein; D051197:Toll-Like Receptor 4; D000068879:Adalimumab